Called the SP-X Imaging and Analysis system, the benchtop platform combines Quanterix's high-sensitivity Simoa assays with higher levels of multiplexing.
Under the agreement, Expedeon will give Quanterix access to its CaptSure immunoassay products along with its Lightning-Link antibody labeling technology.
The company posted Q3 revenues of $10.6 million, up from $5.7 million in Q3 2017 and beating the consensus Wall Street estimate of $8.5 million.
The company's shares grew 28 percent in September after it terminated a licensing deal with BioMérieux and regained control of certain intellectual property.
The company posted Q2 revenues of $8.6 million, up from $5.2 million in Q2 2017 and above the consensus Wall Street estimate of $7.9 million.
The company posted Q1 revenues of $7.5 million, up from $5.3 million in Q1 2017 and above the consensus Wall Street estimate of $7.1 million.
The effort will use Quanterix's Simoa technology and will focus initially on development of an assay for measuring the liver toxicity biomarker microRNA-122.
Near-term the deal gives Quanterix a CLIA lab while securing technologies that could improve assay multiplexing and support its longer term clinical goals.
The company posted Q4 revenues of $6.6 million, down from $6.7 million in Q4 2016 and shy of the consensus Wall Street estimate of $6.7 million.
The company said its recent $74 million IPO was done largely to drive awareness among biotech and pharma firms of its ultrasensitive immunoassay technology.
Customers might want to consider what they might learn about their risk of diseases like Alzheimer's before snagging the genetic testing kits that are on many gift guides this year, NJ.com writes.
The Wall Street Journal reports there is uncertainty surrounding whether He Jiankui's embryo editing did what he said it did.
Stat News reports that the pause on procuring fetal tissue for intramural US National Institutes of Health research will soon affect additional labs there.
In Nature this week: genomic analysis of the invasive fall webworm, amp of constrained coding regions within the human genome, and more.